Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization. (Q42239687)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 January 2014

Language	Label	Description	Also known as
English	Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization.	scientific article published on 29 January 2014

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

vector-borne disease

0 references

0 references

human parainfluenza

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Kenta Watanabe

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Akihiro Matsubara

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Mitsuo Kawano

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Satoru Mizuno

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Tomotaka Okamura

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yusuke Tsujimura

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Hiroyasu Inada

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Tetsuya Nosaka

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yasuhiro Yasutomi

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

0 references

publication date

29 January 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

32

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1727-1735

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Viruses - from pathogens to vaccine carriers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Provision of continuous maturation signaling to dendritic cells by RIG-I-stimulating cytosolic RNA synthesis of Sendai virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

In situ characterization of CD4+ T cell behavior in mucosal and systemic lymphoid tissues during the induction of oral priming and tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Ag85B of mycobacteria elicits effective CTL responses through activation of robust Th1 immunity as a novel adjuvant in DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Disruption of nuclear factor-interleukin-6, a transcription factor, results in severe mycobacterial infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Induction of granulomas in interferon-gamma gene-disrupted mice by avirulent but not by virulent strains of Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Viruses as vaccine vectors for infectious diseases and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Prime-boost vaccination with rBCG/rAd35 enhances CD8⁺ cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Recombinant Sendai viruses expressing different levels of a foreign reporter gene.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Innate immune response induced by gene delivery vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Adjuvants in tuberculosis vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.108

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.11.108

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24486310%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42239687&oldid=2110271969"